Boomerang Medical Raises $20 Million Series B to Advance Pivotal Trial of Neuromodulation in Inflammatory Bowel Disease

Boomerang Medical, Inc., a women-led bioelectronic medicine company, today announced a $20 million Series B financing co-led by Arboretum Ventures and Hatteras Venture Partners. Proceeds will advance BOOM-IBD2, the first pivotal trial of implantable neuromodulation in inflammatory bowel disease, with an initial focus on ulcerative colitis. The trial is currently enrolling patients at leading medical centers across the U.S. (NCT06571669).